Selected research
Industry Research
Liver Cirrhosis Therapeutics Industry Research Report 2026
Market perspective
The global Liver Cirrhosis Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Liver Cirrhosis Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Liver Cirrhosis Therapeutics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Liver Cirrhosis Therapeutics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Liver Cirrhosis Therapeutics include Bristol-Myers Squibb, Conatus Pharmaceuticals, Gilead Sciences, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals, Norgine and Pharmicell, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Liver Cirrhosis Therapeutics market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Liver Cirrhosis Therapeutics Market by Company
Bristol-Myers Squibb
Conatus Pharmaceuticals
Gilead Sciences
Gwo Xi Stem Cell Applied Technology
Instituto Grifols
Intercept Pharmaceuticals
NGM Biopharmaceuticals
Norgine
Pharmicell
Salix Pharmaceuticals
Stempeutics Research
GlaxoSmithKline
Roche
Merck
Johnson & Johnson
Liver Cirrhosis Therapeutics Segment by Type
Oral Liver Cirrhosis Therapeutics Drugs
Injection Liver Cirrhosis Therapeutics Drugs
Liver Cirrhosis Therapeutics Segment by Application
Hospitals
Clinics
Other
Liver Cirrhosis Therapeutics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liver Cirrhosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liver Cirrhosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liver Cirrhosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Liver Cirrhosis Therapeutics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Liver Cirrhosis Therapeutics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Liver Cirrhosis Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Liver Cirrhosis Therapeutics Drugs
- Injection Liver Cirrhosis Therapeutics Drugs
Applications
- Hospitals
- Clinics
- Other
Companies covered
- Bristol-Myers Squibb
- Conatus Pharmaceuticals
- Gilead Sciences
- Gwo Xi Stem Cell Applied Technology
- Instituto Grifols
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Norgine
- Pharmicell
- Salix Pharmaceuticals
- Stempeutics Research
- GlaxoSmithKline
- Roche
- Merck
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Liver Cirrhosis Therapeutics Market Size (2021-2032)
- 2.2.2 Global Liver Cirrhosis Therapeutics Sales (2021-2032)
- 2.2.3 Global Liver Cirrhosis Therapeutics Market Average Price (2021-2032)
- 2.3 Liver Cirrhosis Therapeutics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Liver Cirrhosis Therapeutics Drugs
- 2.3.3 Injection Liver Cirrhosis Therapeutics Drugs
- 2.4 Liver Cirrhosis Therapeutics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Liver Cirrhosis Therapeutics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Liver Cirrhosis Therapeutics Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Liver Cirrhosis Therapeutics Revenue of Manufacturers (2021-2026)
- 3.4 Global Liver Cirrhosis Therapeutics Average Price by Manufacturers (2021-2026)
- 3.5 Global Liver Cirrhosis Therapeutics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Liver Cirrhosis Therapeutics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Liver Cirrhosis Therapeutics, Product Type & Application
- 3.8 Global Manufacturers of Liver Cirrhosis Therapeutics, Established Date
- 3.9 Global Liver Cirrhosis Therapeutics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol-Myers Squibb
- 4.1.1 Bristol-Myers Squibb Company Information
- 4.1.2 Bristol-Myers Squibb Business Overview
- 4.1.3 Bristol-Myers Squibb Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol-Myers Squibb Liver Cirrhosis Therapeutics Product Portfolio
- 4.1.5 Bristol-Myers Squibb Recent Developments
- 4.2 Conatus Pharmaceuticals
- 4.2.1 Conatus Pharmaceuticals Company Information
- 4.2.2 Conatus Pharmaceuticals Business Overview
- 4.2.3 Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Conatus Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
- 4.2.5 Conatus Pharmaceuticals Recent Developments
- 4.3 Gilead Sciences
- 4.3.1 Gilead Sciences Company Information
- 4.3.2 Gilead Sciences Business Overview
- 4.3.3 Gilead Sciences Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gilead Sciences Liver Cirrhosis Therapeutics Product Portfolio
- 4.3.5 Gilead Sciences Recent Developments
- 4.4 Gwo Xi Stem Cell Applied Technology
- 4.4.1 Gwo Xi Stem Cell Applied Technology Company Information
- 4.4.2 Gwo Xi Stem Cell Applied Technology Business Overview
- 4.4.3 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gwo Xi Stem Cell Applied Technology Liver Cirrhosis Therapeutics Product Portfolio
- 4.4.5 Gwo Xi Stem Cell Applied Technology Recent Developments
- 4.5 Instituto Grifols
- 4.5.1 Instituto Grifols Company Information
- 4.5.2 Instituto Grifols Business Overview
- 4.5.3 Instituto Grifols Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Instituto Grifols Liver Cirrhosis Therapeutics Product Portfolio
- 4.5.5 Instituto Grifols Recent Developments
- 4.6 Intercept Pharmaceuticals
- 4.6.1 Intercept Pharmaceuticals Company Information
- 4.6.2 Intercept Pharmaceuticals Business Overview
- 4.6.3 Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Intercept Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
- 4.6.5 Intercept Pharmaceuticals Recent Developments
- 4.7 NGM Biopharmaceuticals
- 4.7.1 NGM Biopharmaceuticals Company Information
- 4.7.2 NGM Biopharmaceuticals Business Overview
- 4.7.3 NGM Biopharmaceuticals Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 NGM Biopharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
- 4.7.5 NGM Biopharmaceuticals Recent Developments
- 4.8 Norgine
- 4.8.1 Norgine Company Information
- 4.8.2 Norgine Business Overview
- 4.8.3 Norgine Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Norgine Liver Cirrhosis Therapeutics Product Portfolio
- 4.8.5 Norgine Recent Developments
- 4.9 Pharmicell
- 4.9.1 Pharmicell Company Information
- 4.9.2 Pharmicell Business Overview
- 4.9.3 Pharmicell Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pharmicell Liver Cirrhosis Therapeutics Product Portfolio
- 4.9.5 Pharmicell Recent Developments
- 4.10 Salix Pharmaceuticals
- 4.10.1 Salix Pharmaceuticals Company Information
- 4.10.2 Salix Pharmaceuticals Business Overview
- 4.10.3 Salix Pharmaceuticals Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Salix Pharmaceuticals Liver Cirrhosis Therapeutics Product Portfolio
- 4.10.5 Salix Pharmaceuticals Recent Developments
- 4.11 Stempeutics Research
- 4.11.1 Stempeutics Research Company Information
- 4.11.2 Stempeutics Research Business Overview
- 4.11.3 Stempeutics Research Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Stempeutics Research Liver Cirrhosis Therapeutics Product Portfolio
- 4.11.5 Stempeutics Research Recent Developments
- 4.12 GlaxoSmithKline
- 4.12.1 GlaxoSmithKline Company Information
- 4.12.2 GlaxoSmithKline Business Overview
- 4.12.3 GlaxoSmithKline Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 GlaxoSmithKline Liver Cirrhosis Therapeutics Product Portfolio
- 4.12.5 GlaxoSmithKline Recent Developments
- 4.13 Roche
- 4.13.1 Roche Company Information
- 4.13.2 Roche Business Overview
- 4.13.3 Roche Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Roche Liver Cirrhosis Therapeutics Product Portfolio
- 4.13.5 Roche Recent Developments
- 4.14 Merck
- 4.14.1 Merck Company Information
- 4.14.2 Merck Business Overview
- 4.14.3 Merck Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Merck Liver Cirrhosis Therapeutics Product Portfolio
- 4.14.5 Merck Recent Developments
- 4.15 Johnson & Johnson
- 4.15.1 Johnson & Johnson Company Information
- 4.15.2 Johnson & Johnson Business Overview
- 4.15.3 Johnson & Johnson Liver Cirrhosis Therapeutics Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Johnson & Johnson Liver Cirrhosis Therapeutics Product Portfolio
- 4.15.5 Johnson & Johnson Recent Developments
5 Global Liver Cirrhosis Therapeutics Market Scenario by Region
- 5.1 Global Liver Cirrhosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Liver Cirrhosis Therapeutics Sales by Region: 2021-2032
- 5.2.1 Global Liver Cirrhosis Therapeutics Sales by Region: 2021-2026
- 5.2.2 Global Liver Cirrhosis Therapeutics Sales by Region: 2027-2032
- 5.3 Global Liver Cirrhosis Therapeutics Revenue by Region: 2021-2032
- 5.3.1 Global Liver Cirrhosis Therapeutics Revenue by Region: 2021-2026
- 5.3.2 Global Liver Cirrhosis Therapeutics Revenue by Region: 2027-2032
- 5.4 North America Liver Cirrhosis Therapeutics Market Facts & Figures by Country
- 5.4.1 North America Liver Cirrhosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Liver Cirrhosis Therapeutics Sales by Country (2021-2032)
- 5.4.3 North America Liver Cirrhosis Therapeutics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Liver Cirrhosis Therapeutics Market Facts & Figures by Country
- 5.5.1 Europe Liver Cirrhosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Liver Cirrhosis Therapeutics Sales by Country (2021-2032)
- 5.5.3 Europe Liver Cirrhosis Therapeutics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Liver Cirrhosis Therapeutics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Liver Cirrhosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Liver Cirrhosis Therapeutics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Liver Cirrhosis Therapeutics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Liver Cirrhosis Therapeutics Market Facts & Figures by Country
- 5.7.1 South America Liver Cirrhosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Liver Cirrhosis Therapeutics Sales by Country (2021-2032)
- 5.7.3 South America Liver Cirrhosis Therapeutics Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Liver Cirrhosis Therapeutics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Liver Cirrhosis Therapeutics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Liver Cirrhosis Therapeutics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Liver Cirrhosis Therapeutics Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Liver Cirrhosis Therapeutics Sales by Type (2021-2032)
- 6.1.1 Global Liver Cirrhosis Therapeutics Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Liver Cirrhosis Therapeutics Sales Market Share by Type (2021-2032)
- 6.2 Global Liver Cirrhosis Therapeutics Revenue by Type (2021-2032)
- 6.2.1 Global Liver Cirrhosis Therapeutics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Liver Cirrhosis Therapeutics Revenue Market Share by Type (2021-2032)
- 6.3 Global Liver Cirrhosis Therapeutics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Liver Cirrhosis Therapeutics Sales by Application (2021-2032)
- 7.1.1 Global Liver Cirrhosis Therapeutics Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Liver Cirrhosis Therapeutics Sales Market Share by Application (2021-2032)
- 7.2 Global Liver Cirrhosis Therapeutics Revenue by Application (2021-2032)
- 7.2.1 Global Liver Cirrhosis Therapeutics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Liver Cirrhosis Therapeutics Revenue Market Share by Application (2021-2032)
- 7.3 Global Liver Cirrhosis Therapeutics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Liver Cirrhosis Therapeutics Value Chain Analysis
- 8.1.1 Liver Cirrhosis Therapeutics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Liver Cirrhosis Therapeutics Production Mode & Process
- 8.2 Liver Cirrhosis Therapeutics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Liver Cirrhosis Therapeutics Distributors
- 8.2.3 Liver Cirrhosis Therapeutics Customers
9 Global Liver Cirrhosis Therapeutics Analyzing Market Dynamics
- 9.1 Liver Cirrhosis Therapeutics Industry Trends
- 9.2 Liver Cirrhosis Therapeutics Industry Drivers
- 9.3 Liver Cirrhosis Therapeutics Industry Opportunities and Challenges
- 9.4 Liver Cirrhosis Therapeutics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst